Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014:2014:647541.
doi: 10.1155/2014/647541. Epub 2014 Feb 6.

Tumour markers and kidney function: a systematic review

Giuseppe Coppolino  1 , Davide Bolignano  2 , Laura Rivoli  1 , Giuseppe Mazza  1 , Piera Presta  1 , Giorgio Fuiano  1
Affiliations
Meta-Analysis

Tumour markers and kidney function: a systematic review

Giuseppe Coppolino et al. Biomed Res Int. 2014.

Abstract

Tumour markers represent useful tools in diagnosis and clinical management of patients with cancer, because they are easy to use, minimally invasive, and easily measured in either blood or urine. Unfortunately, such an ideal marker, as yet, does not exist. Different pathological states may increase the level of a tumour marker in the absence of any neoplasia. Alternatively, low levels of tumour markers could be also found in the presence of neoplasias. We aimed at reviewing studies currently available in the literature examining the association between tumour markers and different renal impairment conditions. Each tumour marker was found to be differently influenced by these criteria; additionally we revealed in many cases a lack of available published data.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of the literature selection process.
See this image and copyright information in PMC

References

    1. Handy B. The clinical utility of tumor markers. Laboratory Medicine. 2009;40(2):99–103.
    1. Bidart J-M, Thuiller F, Augereau C, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clinical Chemistry. 1999;45(10):1695–1707. - PubMed
    1. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK) Nature Clinical Practice Oncology. 2005;2(8):416–422. - PubMed
    1. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Medicine. 2012;10, article 51 - PMC - PubMed
    1. Plebani M, Giacomini A, Beghi L, et al. Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation. Anticancer Research. 1996;16(4B):2249–2252. - PubMed

Substances

LinkOut - more resources